Given their critical role, incretin-based therapies including GLP-1 receptor agonists and DPP4 inhibitors have become major treatment strategies for T2DM and obesity [83,110,111]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.